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Abstract
Background
Colorectal cancer (CRC) is the second leading cause of 
cancer-related deaths in the United States. CRC screening 
allows for prevention through the removal of precancerous 
lesions and early detection of cancer.
Community Context
Ride for Life Alaska (RFL), a nonprofit organization 
that raises funds to fight cancer, and the Anchorage 
Neighborhood Health Center (ANHC), which is Alaska’s 
largest community health center, joined efforts to provide 
CRC screening and outreach to an ethnically diverse 
group of low-income underinsured or uninsured patients 
residing in and around Anchorage, Alaska.
Methods
RFL and ANHC worked with gastroenterologists, medical 
practices, and pathology services to contribute pro bono 
and reduced-fee services for CRC screening. Information 
to patients was distributed through signs in the clinic, fly-
ers, and the ANHC website.
Outcomes
CRC screening was increased in this population. During 
2007-2009, there were 2,561 immunochemical fecal occult 
blood tests given to patients, and 1,558 were completed 
(61%); 24% were positive. Sixteen gastroenterologists, 4 
medical practices, and 2 laboratories provided 111 follow-
up colonoscopies and pathology services to patients identi-
fied through the CRC screening program who did not have 
other funding resources available for follow-up care.
Interpretation
This program provides a model for leveraging scarce 
screening resources by drawing on multiple partners to 
increase CRC screening. Recommendations for those seek-
ing to initiate similar programs are to have memoranda 
of agreement in place and a clear scope of work for all 
participating people and organizations to avoid delays in 
program implementation; hire a screening care coordina-
tor to manage patient care and collaborate with medical 
practices; and identify program champions who have the 
energy and persistence to craft such partnerships.
Background
Colorectal cancer (CRC) is the second leading cause of can-
cer-related deaths in the United States. In 2009, an esti-
mated 150,000 people had CRC diagnosed and 50,000 died 
from the disease (1). CRCs can develop from slow-growing 
adenomatous polyps in the colon and rectum. Screening 
for CRC allows the identification and removal of precan-
cerous lesions and early detection of cancers (2-4). Various 
screening modalities reduce CRC deaths. Annual fecal 
occult blood tests (FOBTs) or colonoscopy every 10 years 
are both CRC screening tests recommended by the US 
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Preventive Services Task Force (USPSTF) (4). However, 
screening for this disease is underused, especially among 
people with low income, the underinsured and uninsured, 
and minorities (5,6). Some reasons for low screening rates 
include confusion regarding which test to perform of the 
many options available, lack of awareness of the need for 
screening or fear of screening among potential patients, 
and cost and capacity issues (7-9).
Community Context
We describe the development, implementation, and out-
come of a partnership between a fund-raising organization, 
Ride for Life Alaska (RFL), and a community health cen-
ter, the Anchorage Neighborhood Health Center (ANHC). 
The objective of the partnership is to increase the number 
of CRC screenings completed by low-income underinsured 
and uninsured patients. To provide more screenings, the 
partnership engages the medical community: primary care 
providers and specialty care providers, including gastroen-
terologists, medical practices, and pathology services.
ANHC began providing primary care services in 1971 and 
has become 1 of Alaska’s largest primary care medical 
practices. ANHC revenue comes from the following sourc-
es: Medicaid/Medicare (56%), private insurance (25%), 
and self-pay by patients (19%). However, grants make up 
a substantial portion (38%) of the total operating budget. 
ANHC is a federally qualified health center and is Alaska’s 
largest community health center, serving 11,500 patients 
through 40,000 visits per year. More than half of patients 
(58%) are at or below the federal poverty level, and only 
18% of patients have private insurance. The patient 
population is ethnically diverse, and more than half (59%) 
report a nonwhite ethnicity. Asians/Pacific Islanders make 
up 20% of patients, followed by Hispanics/Latinos (12%), 
African Americans (12%), and Alaska Natives (2%). There 
is also a diversity of languages spoken by patients, includ-
ing Spanish, Samoan, Korean, and Hmong. The popula-
tion served has more women (56%) than men (44%), and 
46% are aged 45 years or older.
RFL was founded in 2004 by Anchorage resident Larry 
Holman after he was diagnosed with stage 3 CRC. While in 
treatment, Holman and several friends and acquaintances 
began planning a 2-day, 125-mile bicycle ride through 2 
scenic mountain passes from Anchorage to Seward, Alaska 
(Figure 1). Originally intended as a way for Holman to 
celebrate and appreciate his life, friends, and family, the 
ride turned into a cancer fundraiser. Holman, having just 
experienced the personal effects of CRC, felt passionately 
about raising funds for cancer prevention and education. A 
core group of volunteers joined efforts to move the project 
forward. Event coordination included gathering all neces-
sary permits and insurance, advertising with bicycle clubs 
and outdoor groups, and setting up camping space, food, 
rest stops, support stations, and transportation for partici-
pants back to Anchorage after the ride. The first night of 
the ride also includes a “Celebration of Life” dinner, which 
features speakers and riders sharing their cancer experi-
ences and honoring those who have died of cancer.
 
Figure 1. Ride for Life Alaska fundraiser bicycle participants, 2007
The first ride in August 2004 was a success and became 
an annual ride that grossed $120,000 in cash and in-
kind contributions in 2009. RFL incorporated as a 501(c) 
nonprofit in December 2004. For the first 2 years, RFL 
donated funds raised to the Lance Armstrong Foundation 
Peloton Project. The Lance Armstrong Foundation had 
good name recognition for riders, a mechanism in place 
to donate funds via the Internet, and low administrative 
costs compared with other nonprofit groups.
In 2006, the state of Alaska and the Alaska Tribal 
Comprehensive Cancer Control Programs contacted RFL 
and suggested that the money raised be used locally to fund 
a CRC screening program for Alaska residents instead of 
directed solely toward the national Peloton Project. RFL 
contacted ANHC to explore setting up a partnership to 
promote CRC screening among low-income and underin-
sured ANHC patients. Before this partnership, there were 
no community-based CRC screening services available 
for low-income patients. ANHC offered $10 FOBT kits 
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to patients on request, but the cost was still a barrier to 
the neediest patients. Before initiation of the partnership, 
only about 200 kits were distributed each year. RFL and 
ANHC signed a memorandum of agreement in 2007. This 
type of collaboration between a fundraising organization 
and a health facility had never been attempted in Alaska 
before. Additionally, although ANHC had patients in need 
of screening, it did not have the capacity to provide all the 
elements necessary for a comprehensive screening pro-
gram, including follow-up for positive screening exams.
Methods
Engaging the medical community
In 2006, RFL and ANHC invited members of the Anchorage 
medical community to participate in the initiative to increase 
CRC screening among the ANHC patient population. Staff 
from the 2 organizations called, sent letters, and e-mailed 
the 16 gastroenterologists working in the Anchorage area. 
All Anchorage gastroenterologists in private practice agreed 
to provide pro bono colonoscopies. The private endoscopy 
centers in which the endoscopy providers worked agreed to 
provide discounted facility fees. The laboratories that pro-
cessed their specimens then agreed to provide discounted 
pathology services. This initial phase of engaging the medi-
cal community took about a year to set up memoranda of 
agreement among all the parties involved.
Key to engaging the private gastroenterologists was the 
development of mutually agreeable criteria for referral. 
ANHC developed a flow chart (Figure 2) designed to 
keep the referrals to strictly “screening” referrals (4,10). 
Patients with high-risk signs or symptoms, such as frank 
rectal bleeding or weight loss, were routed to definitive 
referrals through a more urgent process. ANHC also used 
immunochemical FOBT (iFOBT) kits rather than the more 
common and less expensive guaiac-based tests in hopes 
that the false-positive rate might be reduced, reasoning 
that the up-front investment in specificity would reduce 
the burden on the volunteer gastroenterologists.
Early in the program, ANHC tried to train its medi-
cal staff to provide screening by flexible sigmoidoscopy. 
However, it was difficult for staff to get enough training 
on practice patients and, once trained, to find time to do 
procedures among competing clinical demands. Because of 
these issues, the focus of the program shifted away from 
in-house flexible sigmoidoscopy and toward use of iFOBTs 
with positive follow-up colonoscopy referrals at participat-
ing private medical practices.
Initially, RFL provided funding only for the direct screen-
ing services: iFOBT kits and colonoscopy reimbursements. 
ANHC medical staff provided in-kind support for most 
of the project management, coordination, and referrals. 
However, this approach was burdensome to staff and did 
not lead to the desired increase in screening. In 2008, 
RFL agreed to fund a part-time staff position at ANHC 
for a screening care coordinator. After the creation of this 
position, screening numbers under the program increased 
substantially.
Engaging the patient community
The screening program design was based on ANHC’s pre-
vious vaccination outreach campaigns. Signs were placed 
throughout the clinic and in examination rooms, patient 
Figure 2. Referral flow chart, Anchorage Neighborhood Health Center, 2009. 
Note: FOBT should be performed on all referrals. A negative test does not 
necessarily deflect referral when appropriate but is helpful collateral infor-
mation. Definitions: intermediate risk, no specific gastrointestinal symptoms 
and either family history or weight loss; high-risk, a person with a history of 
colon cancer, first degree family history, or change in stool pattern and rectal 
bleeding or unexplained weight loss. Abbreviations: FOBT, fecal occult blood 
test; APA, Anchorage Project Access; RFL, Ride for Life Alaska funding; flex 
sig, flexible sigmoidoscopy; GI, gastrointestinal; sxs, symptoms.
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flyers were sent, and information was posted on the ANHC 
website. Holman and the medical director appeared with a 
private gastroenterologist on a local health care talk radio 
show to promote the screening program.
ANHC patients aged 50 to 70 years are sent an annual 
postcard during Colorectal Cancer Awareness Month 
(March) inviting them to pick up a free iFOBT kit at the 
clinic. Patients are identified as due for screening by using 
the ANHC electronic health record system or are referred 
to the program by ANHC providers; patients also may 
request the screening directly. Patients who bring back 
their completed iFOBT receive a $5 grocery store gift card. 
ANHC staff analyze the iFOBTs in an on-site laboratory.
The ANHC screening care coordinator contacts all patients 
with positive iFOBTs to come in to ANHC for follow-up 
according to a flow chart based on recommendations from 
the USPSTF and the American Cancer Society (Figure 2). 
Patients who have insurance are referred to private endos-
copy centers for follow-up. Patients without insurance 
are invited to participate in the RFL-funded colonoscopy 
program. For these patients, the ANHC screening care 
coordinator reviews the patient’s medical history and goes 
over the colonoscopy preparation and procedure instruc-
tions with the patient. The screening care coordinator 
then schedules the patient for a colonoscopy with 1 of the 
participating gastroenterologists at a private endoscopy 
center.
Payments and reimbursements
After the colonoscopy appointment, the endoscopy center 
submits a payment authorization voucher to ANHC for 
reimbursement. The payment is $700, which covers about 
one-third of the overhead expense associated with the colo-
noscopy procedure (no physician fees are included). Under 
Alaska’s Good Samaritan Law, because the providers waive 
their physician fees, they are immune from civil damages 
resulting from their services, with certain exceptions (eg, 
gross negligence) (11). Two laboratories process all of the 
pathology samples. The laboratories provide this service 
at a discounted flat rate of $75 per sample. RFL funds pay 
for the purchase and processing of the iFOBT kits, mailing 
and postage, patient incentives, and the salary of the part-
time ANHC screening care coordinator. Should patients 
need further treatment, including further testing, repeat 
procedures, surgery, or hospitalization, payment is worked 
out by using various funding mechanisms.
Outcomes
Medical community
As a result of the efforts to engage the medical community, 
16 doctors, 4 medical practices, and 2 laboratories agreed 
to provide services to ANHC patients identified through 
the CRC screening program (Table). One gastroenterolo-
gist also serves as a champion for the program by directly 
encouraging other colonoscopy providers to participate in 
the program.
Barriers to the program included medical practice man-
agers who were concerned about increased workload due 
to participation and about patient follow-up and care. 
Furthermore, some providers were concerned that if they 
initiated charity care they wouldn’t be able to discontinue 
it. There is also the financial challenge of sustainability, 
which potentially limits the program in duration and scope 
since it depends on the annual fundraising capability of a 
nonprofit organization.
Patient community
The program began outreach efforts to patients in December 
2007 with $35,000 in funding from RFL; in 2008, RFL con-
tributed $60,000. In the first year, 549 iFOBT kits were 
given to patients and 396 (72%) were returned (Table). 
The mean age of patients was 56 years (range, 40-66 y). 
A total of 24% were positive for fecal occult blood, and 7 
uninsured patients received follow-up colonoscopies. No 
advanced polyps (tubular or more severe) were found dur-
ing the exams. In 2008, numbers were similar to 2007 for 
kits distributed and returned. Of 16 uninsured patients 
who got follow-up colonoscopies, 2 had tubular adenomas 
and 1 had CRC diagnosed and treated. In 2009, a total of 
1,390 iFOBT kits were given to patients and 680 (49%) 
were returned. Of those, 24% were positive for fecal occult 
blood. Of 57 colonoscopies completed, 9 were for patients 
who had tubular adenomas detected and removed. In the 
first quarter of 2010, a total of 23 colonoscopies were com-
pleted, and no advanced polyps or cancers were detected.
Challenges that patients face to participating in the pro-
gram include language barriers and difficult living situa-
tions. There is a substantial time commitment required of 
patients who undergo a colonoscopy, including prepara-
tion, travel, waiting, procedure time, and onsite recovery 
(12). Many ANHC patients require translation for the 
colonoscopy instructions, for which ANHC uses a contract 
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service that provides on-call language interpretation. 
This service is expensive but necessary to adequately 
prepare patients for their procedure. ANHC also creates 
some program materials in Spanish to facilitate patient 
comprehension. Colonoscopy preparation includes the use 
of strong laxatives the day before the procedure, which is 
difficult for homeless patients or those living in halfway 
or group housing. Some patients have difficulties finding 
an escort to take them home, which is required because of 
the sedatives administered during the procedure. Despite 
these potential barriers, 93% of ANHC patients scheduled 
for colonoscopies completed the procedure, which shows 
the high level of interest and dedication of these patients 
to accessing CRC screening when offered.
Interpretation
This program provides a model for leveraging scarce 
resources to enable CRC screening for a low-income and 
underinsured and uninsured population. The program 
works by drawing on various partners: a fundraising orga-
nization, a community health center, and members of the 
medical community (specialty care including endoscopy 
and gastroenterology, and pathology services). These part-
nership and community engagement efforts have proved 
highly successful in increasing CRC screening in this 
underserved population.
This program was successful at getting low-income under-
insured and uninsured patients screened for CRC because 
of several factors. The first is the persistence and lead-
ership of Holman, who envisioned how a fundraising 
organization could work collaboratively with a primary 
care center by providing seed money for the initiation of 
a CRC screening program. The second is the trust built 
between ANHC and the community that it serves, which 
allowed the program to target services directly to patients 
in need of screening, resulting in a high iFOBT return 
rate by patients. Third is that by engaging the medical 
community, the program is able to tap into a willingness 
by providers, medical practices, and pathology groups to 
provide pro bono or heavily discounted CRC screening 
services. Lastly, the presence of a dedicated screening care 
coordinator based at ANHC is a necessary component of 
the program; this person is a liaison between the medical 
community members donating their services and patients 
in need of screening. The return rate for the iFOBT sam-
ples was 61%, which is higher than that reported in other 
published studies (13-15). We believe that the presence 
of the screening care coordinator, the support from other 
ANHC staff, and the small patient incentive help explain 
this high rate of adherence.
Recommendations for those seeking to initiate this sort 
of program are to hire at least a part-time screening care 
coordinator to manage the patient scheduling, instruc-
tions, billing, and colonoscopy results in order to facilitate 
appropriate patient care and follow-up. Many safety-net 
medical practices experience frequent staff turnover; 
thus, it is important to keep ongoing contact with people 
to maintain the smooth functioning of the program. A 
key component of such collaboration is to promote clear 
communication between all the groups involved: the phy-
sicians, the pathology services, the primary care facility, 
and the funders. Having memoranda of agreement in 
place is important, as is having a clear scope of work for 
all participating people and organizations to avoid delays 
in program implementation. Continued efforts to develop 
partnerships and engage the medical community will 
increase CRC screening services available and ultimately 
help to decrease deaths from CRC.
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Table
Table. Patients Screened Through the Ride for Life Alaska and Anchorage Neighborhood Health Center Partnership, December 2007-
April 2010
Characteristic N (%)
Status of iFOBTs
Given to patients 2,51 (100)
Returned 1,558 (1)
Positive 37 (2)
Endoscopists participating in referral program 1 (NA)
Patients referred for program-funded colonoscopy 111 (100)
Colonoscopies completed 103 (93)
Colonoscopies cancelled or refused 8 (7)
Reason for referrala (n = 101)
Positive iFOBT 51 (50)
Family history of CRC or polyps 27 (27)
Personal history of CRC or polyps 20 (20)
Screening  ()
Other 3 (3)
Sex (n = 102)
Men 50 (9)
Women 52 (51)
Race (n = 101)
White 3 (3)
African American 15 (15)
Asian/Pacific Islander/American Indian  ()
Unknown 77 (7)
Results (n = 89)
Normal (including hyperplastic polyps) 73 (82)
Tubular adenoma or worse 15 (17)
Colorectal cancer 1 (1)
 
Abbreviations: iFOBT, immunochemical fecal occult blood test; NA, not applicable; CRC, colorectal cancer. 
a Patients could have more than 1 reason for referral.
